News | July 02, 2022
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
